Fesoterodine Explained

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]

Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.

Efficacy

Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.[5] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.[5]

A Japanese study from 2017, showed that urgency and urge incontinence are improved after 3 days administration of the drug, with full efficacy able to be judged after 7 days administration. Overactive bladder was found to be resolved in 88% of patients after seven days usage. [6]

Notes and References

  1. Web site: Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights. 17 April 2006. Medical News Today. 2 November 2007. 16 May 2011. https://web.archive.org/web/20110516020517/http://www.medicalnewstoday.com/articles/41688.php. dead.
  2. Web site: Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08 . 2 June 2008 . . dead . https://web.archive.org/web/20080401005811/http://www.emea.europa.eu/humandocs/Humans/EPAR/toviaz/toviaz.htm . 2008-04-01 .
  3. Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder . Pfizer Inc. . 2008-10-31 . 2008-11-06 . 2018-09-20 . https://web.archive.org/web/20180920075736/https://www.drugs.com/newdrugs/pfizer-s-toviaz-fesoterodine-fumarate-receives-fda-approval-overactive-bladder-1167.html . live .
  4. Web site: Notice of Decision for TOVIAZ . 2012-04-20 . https://web.archive.org/web/20120423124138/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/nd_ad_2012_toviaz_142326-eng.php . 2012-04-23 . dead .
  5. Vella M, Cardozo L . Review of fesoterodine . Expert Opinion on Drug Safety . 10 . 5 . 805–8 . September 2011 . 21639817 . 10.1517/14740338.2011.591377 . 9653506 .
  6. "Sato N, Fuji K, Ogawa Y . 10.15369/sujms.29.201. Transactions of The Showa University Society: The 335th Meeting. The Showa University Journal of Medical Sciences. 29. 2. 201–217. 2017 . 2185-0968. free.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Fesoterodine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.